Zydus Lifesciences shares in focus on USFDA nod for canine drug
Shares of Zydus Lifesciences are likely in focus after its subsidiary, ZyVet Animal Health, launched the first FDA-approved generic treatment for canine urinary incontinence in the U.S. The phenylpropanolamine hydrochloride tablets target aging and spayed female dogs, marking a significant move into the underserved animal generics market and reinforcing ZyVets focus on affordable, high-quality veterinary care.
Shares of Zydus Lifesciences are likely in focus after its subsidiary, ZyVet Animal Health, launched the first FDA-approved generic treatment for canine urinary incontinence in the U.S. The phenylpropanolamine hydrochloride tablets target aging and spayed female dogs, marking a significant move into the underserved animal generics market and reinforcing ZyVets focus on affordable, high-quality veterinary care.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
